Evidence map›Paper›PMID 32449981›Full record

ArticleThe journal of gene medicine2020

Serum lncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer.

Chun-Na Liu, Hai-Yan Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of gene medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The Role of Long Non-Coding RNAs in Ovarian Cancer Cells.International journal of molecular sciences · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chun-Na LiuDepartment of Gynecology, Linyi Cancer Hospital, Linyi, Shandong, China.
Hai-Yan ZhangClinical Laboratory, Linyi Cancer Hospital, Linyi, Shandong, China.ORCID 0000-0002-3699-8672
Linyi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present study aimed to examine the levels of circulating LOXL1-AS1 in epithelial ovarian cancer (EOC) patients and to analyze its diagnostic and prognostic value.

methodsThe levels of LOXL1-AS1 in 185 EOC patients and 43 healthy volunteers were evaluated by a quantitative reverse transcriptase-polymerase chain reaction. The potential of LOXL1-AS1 as a biomarker for EOC diagnosis was determined by receiver-operating characteristic (ROC) curve assays. The associations between clinicopathological parameters and LOXL1-AS1 expression were analyzed using a chi-squared test. The influence of LOXL1-AS1 on overall survival was analyzed by the use of Kaplan-Meier. A Cox proportional hazards assays were conducted for the determination of the prognostic value of LOXL1-AS1.

resultsThe expression of LOXL1-AS1 was dramatically higher in EOC patients compared to healthy controls (p < 0.01). LOXL1-AS1 yielded an area under the ROC curve of 0.843 with 65.3% sensitivity and 68.2% specificity in discriminating high-grade EOC from healthy controls. It was also shown that LOXL1-AS1 expression was associated with advanced FIGO stage (p = 0.004) and positively distant metastasis (p = 0.013). Kaplan-Meier assays revealed that patients with high LOXL1-AS1 expression had a shorter overall survival than those with low expression (p = 0.0006). By performing multivariate assays, LOXL1-AS1 was confirmed to be an independent prognostic factor for predicting the prognosis of EOC patients.

conclusionsWe provide evidence indicating that LOXL1-AS1 expression is correlated with a poor clinical outcome in EOC patients and may act as an independent prognostic indicator, as well as a new diagnostic biomarker.

Indexed as

AgedBiomarkers, TumorCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedPrognosisRNA, Long NoncodingBiomarkers, TumorRNA, Long Noncodingcirculating LOXL1-AS1diagnosisEOClncRNAprognosis

Identifiers

PMID32449981
PMCPMC7685168
OpenAlexW3031815127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.